Membership Update

The ALTG membership currently stands at 487. Prospective members can apply online to become an ALTG member at www.altg.com.au. Please encourage your colleagues to join the group and contact us with their trial ideas. The ALTG can assist in developing an idea into a protocol, seek available funding opportunities and recruiting patients. As a member travel grants are available to attend ALTG meetings/ workshops.

Members by location
NSW 149
VIC 113
QLD 105
WA 41
SA 34
NZ 21
TAS 9
ACT 11
NT 2
Overseas 2

 

Members by craft group
Medical Oncologist 155
Nurse 61
Registrar/ Research Fellow/ Trainee/ Student 51
Respiratory Physician 50
Clinical Trials Co-ordinator/ Manager 43
Radiation Oncologist 30
Scientist/ Researcher 25
Surgeon 19
Consumer 10
Other 10
Pathologist 7
Palliative Care Physician 6
Biostatistician/ Statistician 4
Pharmacist 4
Physiotherapist 4
Psycho-oncology 3
General Practitioner 2
Radiologist 2
Psychologist 1
Upcoming Events
  1. Consumer training workshops

    July 17 @ 12:30 pm - 2:00 pm
  2. Conducting systematic reviews: A short course for thoracic oncology nurses

    August 5 @ 6:30 pm
  3. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 10:00 am - October 24 @ 3:30 pm
  4. ALTG open MAC and SAC meetings

    November 20

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.